Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients

2010 ◽  
Vol 28 (5) ◽  
pp. 360-366 ◽  
Author(s):  
Vanusa Manfredini ◽  
Giovana Brondani Biancini ◽  
Camila Simioni Vanzin ◽  
Anna Maria Ribeiro Dal Vesco ◽  
Franciele Cipriani ◽  
...  
Keyword(s):  
Oxidative Damage ◽  
Whole Blood ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Blood Leukocytes ◽  
Simvastatin Treatment ◽  
Oxidative Damage To Dna ◽  
Type 2 Diabetic

scholarly journals Rapid Detection of the mt3243A > G Mutation Using Urine Sediment in Elderly Chinese Type 2 Diabetic Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-7
Author(s):  
Yinan Zhang ◽  
Xiujuan Du ◽  
Xinqian Geng ◽  
Chen Chu ◽  
Huijuan Lu ◽  
...  
Keyword(s):  
High Resolution ◽  
Peripheral Blood ◽  
High Resolution Melting ◽  
Diabetic Patients ◽  
Peripheral Blood Leukocytes ◽  
Type 2 Diabetic Patients ◽  
Blood Leukocytes ◽  
Urine Sediment ◽  
Type 2 Diabetic

Objective. In this study, we aimed to identify mt3243A > G mutation carriers in a group of Chinese elderly type 2 diabetic patients by a rapid and noninvasive diagnostic system. Methods. DNA was extracted from blood, saliva, and urine sediment samples. The mutation screening and quantitation of heteroplasmy were performed by high-resolution melting (HRM) curve and pyrosequencing, respectively. Patients with mt3243A > G mutation underwent a detailed audiometric, ophthalmologic, neurological, and cardiac examination. Results. Two patients (2/1041) carrying the mt3243A > G mutation were detected among all type 2 diabetic patients. In patient 1, the heteroplasmy was 0.8%, 2.8%, and 14.7% in peripheral blood leukocytes, saliva, and urine sediment, respectively. In patient 2, the heteroplasmy was 5.3%, 8.4%, and 37.7% in peripheral blood leukocytes, saliva, and urine sediment, respectively. Both of the two patients showed hearing impairment. Abnormal ophthalmologic conditions and hyperintensity on T2-weighted magnetic resonance images were showed in patient 1. Conclusion. The occurrence of mt3243 A > G mutation was 0.2% in Chinese elderly type 2 diabetic patients. Moreover, detection of mt3243 A > G mutation in urine sediment with high-resolution melting (HRM) curve and pyrosequencing is feasible in molecular genetic diagnosis.

scholarly journals Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Marijana Vučić Lovrenčić ◽  
Mirjana Pibernik-Okanović ◽  
Mario Šekerija ◽  
Manja Prašek ◽  
Dea Ajduković ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Oxidative Damage ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Treatment As Usual ◽  
Subsyndromal Depression ◽  
One Year ◽  
Type 2 Diabetic

Aims. To examine one-year changes in oxidative damage and inflammation level in type 2 diabetic patients undergoing behavioral treatment for subsyndromal depression.Materials and Methods. A randomized controlled comparison of psychoeducation (A), physical exercise (B), and enhanced treatment as usual (C) was performed in 209 eligible subjects in a tertiary diabetes care setting. Depressive symptoms (primary outcome) and selected biomarkers of oxidative damage and inflammation (secondary outcomes) were assessed at baseline and six- and twelve-month follow-up.Results. Out of the 74, 67, and 68 patients randomised into groups A, B, and C, respectively, 201 completed the interventions, and 179 were analysed. Participants in all three groups equally improved in depressive symptoms from baseline to one-year follow-up (repeated measures ANOVA;F=12.51,p<0.0001,η2=0.07). Urinary 8-oxo-deoxyguanosine (u-8-oxodG) decreased (F=10.66,p<0.0001,η2=0.06), as did sialic acid and leukocytes (F=84.57,η2=0.32andF=12.61,η2=0.07, resp.;p<0.0001), while uric acid increased (F=12.53,p<0.0001,η2=0.07) in all subjects during one year. Improvement of depressive symptoms at 6 months significantly predicted one-year reduction in u-8-oxodG (β=0.15,p=0.044).Conclusion. Simple behavioral interventions are capable not only of alleviating depressive symptoms, but also of reducing the intensity of damaging oxidative/inflammatory processes in type 2 diabetic patients with subsyndromal depression. This trial is registered withISRCTN05673017.

scholarly journals Paradoxical Negative HDL Cholesterol Response to Atorvastatin and Simvastatin Treatment in Chinese Type 2 Diabetic Patients

2013 ◽  
Vol 10 (2-3) ◽  
pp. 213-222 ◽  
Author(s):  
Yu-Hung Chang ◽  
Kun-Cheng Lin ◽  
Dao-Ming Chang ◽  
Chang-Hsun Hsieh ◽  
Lee Yau-Jiunn
Keyword(s):  
Hdl Cholesterol ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Simvastatin Treatment ◽  
Type 2 Diabetic

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Sign in / Sign up

Export Citation Format

Share Document